MELBOURNE, June 10, 2026, 09:05 AEST
Telix Pharmaceuticals looked to outperform the market at the ASX pre-open Wednesday. Shares closed up 0.6% at A$13.39 Tuesday, with the day’s range between A$12.80 and A$13.50. Volume came in around 2.14 million. Telix’s market cap sits near A$4.54 billion. The stock is still trading below its 52-week high of A$26.25, but above the A$8.26 low.
The move is notable since the wider Australian market dropped. The S&P/ASX 200 shed 0.24% to end at 8,604.20 on Tuesday. Healthcare stocks offered some support after a steep selloff at the open.
As of the dateline, ASX cash market was in pre-open, with orders able to be placed but not matched. Regular trading picks up just before 10 a.m. Sydney time and continues until 4 p.m. Monday was closed for the King’s Birthday, leaving Tuesday as the start of the week for cash trading.
ASX 200 futures added 13 points, or 0.15%, at 8:25 a.m. AEST, Market Index said. Local leads offered limited support after Wall Street closed mixed, the Nasdaq dipping while the Dow ticked up.
Telix hasn’t posted a new clinical filing in its latest company-announcement section. The latest update is a “change in substantial holding” from June 9, with Listcorp listing JPMorgan Chase & Co. and affiliates as the substantial holder. These filings usually just show changes in major shareholder stakes, rather than giving fresh operating news. Intelligent Investor Listcorp
Telix’s core business is still radiopharmaceuticals. In April, the company put out unaudited first-quarter group revenue at US$230 million, which rose 24% from last year and 11% over the prior quarter. It also kept its 2026 revenue outlook at US$950 million to US$970 million. CEO Christian Behrenbruch said Illuccix and Gozellix drove the solid base for future growth in the prostate cancer imaging segment.
Investors got a look at new trial results this week. At ASCO 2026, Telix reported Part 1 data from ProstACT Global, its Phase 3 TLX591-Tx trial in metastatic castration-resistant prostate cancer, saying tolerability was in line with expectations and there were no new safety issues. Pedro C. Barata, principal investigator, called the data supportive of moving to the randomized stage. Chief Medical Officer David Cade said patients run short on first- and second-line therapies.
Telix and United Imaging Healthcare North America have signed an MOU to look at a U.S. theranostics collaboration, the companies said. The initial focus is TLX101-Px, Telix’s brain cancer imaging candidate. Telix Precision Medicine CEO Kevin Richardson called the effort an attempt to build “more seamless, data-driven workflow solutions.” Telix Pharmaceuticals
Telix shares outperformed on a mixed day for rivals. Clarity Pharmaceuticals, another radiopharma stock listed on the ASX, was last at A$2.15, down 4.44%, according to Reuters. CSL added 1.59% to A$99.47, as per Intelligent Investor. Part of Telix’s move looked like a stock-specific trade, but the gain also happened as defensive healthcare names found buyers while mining stocks struggled.
But the main risk is still around regulation and execution. A number of Telix’s pipeline candidates mentioned in recent updates haven’t won marketing approval. The company’s EU submission for TLX101-Px is still under review. Last year, the FDA asked for more data on the firm’s kidney cancer diagnostic candidate, and that demand hit Telix’s share price as manufacturing and supply-chain issues came up.
Telix faces a straightforward test at Wednesday’s open—buyers need to keep shares above Tuesday’s close when the ASX starts trading again. But the stock could slip if biotech risk hits the sector. Broader market signals are a bit positive, though TLX is still tied to trial news, FDA updates, and how shareholders move money in and out.
